top of page

Seed Grant Program

The Need for ROS1+ Research

ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer and other types of cancer. While oral targeted therapies are approved to treat it, the drugs don’t work for everyone, and they eventually stop working. We need more research to learn more about ROS1 biology, find better treatments, and improve quality of life and survival for all patients with this disease.

​

What We Fund

The ROS1+ Cancer Innovation Award seeks high-risk, high-reward research projects focused on ROS1+ cancer. The award provides a one-year grant of up to $75,000 to fund pre-clinical, translational, or clinical research critical to improve outcomes for ROS1+ cancer. The program is open to investigators who hold a doctorate and a faculty appointment anywhere in the world. We aim to fund three awards in 2025.

​

How to Apply

ROS1+ Cancer Innovation Award uses a two-step application process: a Letter of Intent followed by a Full Application.  Templates and detailed instructions for applying can be found at proposalcentral.com. Be sure to read those instructions in case any instructions were changed, added, or deleted after this RFA was issued. For more information about this opportunity, please see the ROS1+ Cancer Innovation Award Request for Application and our press release about the RFA.​

Important Dates

All deadlines occur at 11:59 pm Eastern Time on the stated dates.

RFA Issued
02/10/2025
Letter of Intent Deadline
03/17/2025
Successful LOIs Invited to Submit Full Application
05/05/2025
Full Application Deadline
06/23/2025
Successful Awardees Notified
09/30/2025
bottom of page